Protein Summary
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly and neuronal surface expression of large-conductance calcium-activated potassium channels in brain regions involved in memory and learning via its interaction with KCNT1. Binding of pomalidomide and other thalidomide-related drugs changes the substrate specificity of the human protein, leading to decreased degradation of MEIS2 and other target proteins and increased degradation of MYC, IRF4, IKZF1 and IKZF3. This gene encodes a protein related to the Lon protease protein family. In rodents and other mammals this gene product is found in the cytoplasm localized with a calcium channel membrane protei ...more
- ENST00000231948
- ENSP00000231948
- ENSG00000113851
- ENST00000432408
- ENSP00000412499
- MRT2
- MRT2A
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
kinase perturbation | 0.98 | ||
transcription factor perturbation | 0.97 | ||
protein complex | 0.93 | ||
transcription factor binding site profile | 0.73 | ||
cellular component | 0.72 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 336.04 (req: < 5)
Gene RIFs: 46 (req: <= 3)
Antibodies: 123 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 336.04 (req: >= 5)
Gene RIFs: 46 (req: > 3)
Antibodies: 123 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 6
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 8
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 3
Expression Data (0 Tissues)
Protein Sequence and Structure
Residue Counts
Protein Sequence
ProtVista Viewer
Related Tools (4)

TIGA scores and ranks GWAS discovered associations according to the quantity and quality of the evidence supporting the association.

GENEVA (GENe Expression Variance Analysis) allows you to identify RNA-sequencing datasets from the Gene Expression Omnibus (GEO) that contain conditions modulating a gene or a gene signature.

GlyGen is a data integration and dissemination project for carbohydrate and glycoconjugate related data.

ARCHS4 provides access to gene-function predictions based on RNA-seq co-expression, and gene expression levels across cell and tissues.
Approved Drugs (3)
Active Ligands (8)
Protein-Protein Interactions (90)
KHDRBS2
Novelty: 0.01986638
p_int: 0.999520777
p_ni: 0.000056255
p_wrong: 0.000422968
Data Source: BioPlex
TGIF2LY
Family: TF
p_int: 0.999460339
p_ni: 0.000447661
p_wrong: 0.000092001
Data Source: BioPlex
PDK1
Family: Kinase
Novelty: 0.0078496
p_int: 0.998900553
p_ni: 0.001077012
p_wrong: 0.000022435
Score: 0.234
Data Source: BioPlex,STRINGDB
S100A4
Novelty: 0.00136919
p_int: 0.995320142
p_ni: 0.000191774
p_wrong: 0.004488084
Data Source: BioPlex
CUL4A
Novelty: 0.00917788
p_int: 0.989974102
p_ni: 0.010025898
Score: 0.993
Data Source: BioPlex,STRINGDB
COPS8
Novelty: 0.0408885
p_int: 0.966667163
p_ni: 0.014599138
p_wrong: 0.018733699
Score: 0.549
Data Source: BioPlex,STRINGDB
CUL4B
Novelty: 0.0133075
p_int: 0.960227888
p_ni: 0.039772112
Score: 0.977
Data Source: BioPlex,STRINGDB
GLMN
Novelty: 0.01940401
p_int: 0.943713911
p_ni: 0.005477234
p_wrong: 0.050808855
Score: 0.801
Data Source: BioPlex,STRINGDB
CFP
Novelty: 0.00063251
p_int: 0.941797161
p_ni: 0.009356731
p_wrong: 0.048846108
Score: 0.19
Data Source: BioPlex,STRINGDB
CAVIN1
Family: Enzyme
Novelty: 0.00780634
p_int: 0.811988635
p_ni: 0.000659427
p_wrong: 0.187351937
Score: 0.185
Data Source: BioPlex,STRINGDB
Nearest Tclin Targets
Pathways (1)
UniProt (1)
Data Source | Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|---|
UniProt | Protein modification; protein ubiquitination. | ||||
Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|
Protein modification; protein ubiquitination. | ||||
Viral Interactions (0)
Gene Ontology Terms (11)
Functions (1)
Components (5)
Processes (5)
GO Term | Evidence | Assigned by | ||
---|---|---|---|---|
Inferred from Electronic Annotation (IEA) | UniProtKB-KW | |||
Disease Associations (null)
GWAS Traits (9)
Items per page:
1 – 5 of 9
GWAS Trait | EFO ID | Study Count | SNP Count | Beta Count | Odds Ratio | Evidence (Mean Rank Score) | Provenance | ||
---|---|---|---|---|---|---|---|---|---|
eosinophil count | 4 | 5 | 7 | 98 | |||||
eosinophil percentage of leukocytes | 2 | 7 | 7 | 97.5 | |||||
basophil percentage of leukocytes | 2 | 5 | 6 | 94.2 | |||||
basophil count | 4 | 5 | 8 | 93.5 | |||||
basophil percentage of granulocytes | 1 | 3 | 3 | 91.1 | |||||
Items per page:
1 – 5 of 9
GWAS Trait | EFO ID | Beta Count | Odds Ratio | Evidence (Mean Rank Score) | Provenance | ||
---|---|---|---|---|---|---|---|
eosinophil count | 7 | 98 | |||||
eosinophil percentage of leukocytes | 7 | 97.5 | |||||
basophil percentage of leukocytes | 6 | 94.2 | |||||
basophil count | 8 | 93.5 | |||||
basophil percentage of granulocytes | 3 | 91.1 | |||||
Find similar targets by:
IDG Resources
Orthologs (14)
1 – 5 of 14
Species | Name | Source ID | Gene ID | OMA | EggNOG | Inparanoid | ||
---|---|---|---|---|---|---|---|---|
Chimp | cereblon | VGNC:1790 | 460130 | |||||
Macaque | cereblon | 704436 | ||||||
Mouse | MGI:1913277 | 58799 | ||||||
Rat | RGD:1310533 | 297498 | ||||||
Horse | cereblon | VGNC:16851 | 100052958 | |||||
Publication Statistics
PubMed Score 336.04
PubMed score by year
PubTator Score 85.31
PubTator score by year
Related Publications
Text Mined References (61)
GeneRif Annotations (46)
Items per page:
0 of 0
PMID | Year | Title |
---|